ESiOR Oy (Finland)

Recent papers from ESiOR Oy (Finland)

1. Baseline characteristics and antihypertensive patterns in Finnish patients with hypertension and kidney diseaseEuropean Heart Journal · 2026
2. Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 modelEuropean Heart Journal · 2026
3. Direct and indirect costs associated with declining distance visual acuity: A nationwide longitudinal cost‐of‐illness study with 11‐year follow‐upActa Ophthalmologica · 2026
4. Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort studyTyöväentutkimus Vuosikirja · 2025
5. Societal costs of decreased visual acuity: A Finnish cohort study with 15 years of registry data follow‐upActa Ophthalmologica · 2025
6. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A Meta-AnalysisOphthalmology and Therapy · 2024
7. Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH)JHLT Open · 2024
8. Risk-Stratified Analysis of Long-Term Clinical Outcomes and Cumulative Costs in Finnish Patients with Recent Acute Coronary Syndrome or Coronary Revascularisation: A 5-Year Real-World Study Using Electronic Health RecordsEuropean Heart Journal Open · 2024
9. Price tag of glaucoma care is minor compared with the total direct and indirect costs of glaucoma: Results from nationwide survey and register dataPLoS ONE · 2023
10. Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in FinlandTyöväentutkimus Vuosikirja · 2023
11. Nurse leaders' perceptions of workload and task distribution in public healthcare: A qualitative explorative studyJournal of Clinical Nursing · 2022
12. Advantages in Management and Remote Monitoring of Intravenous Therapy: Exploratory Survey and Economic Evaluation of Gravity-Based Infusions in FinlandAdvances in Therapy · 2022
13. Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life ChallengeMedical Decision Making · 2021
14. Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial FibrillationClinicoEconomics and Outcomes Research · 2021
15. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based studyBMJ Open · 2021
16. A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in FinlandTyöväentutkimus Vuosikirja · 2021
17. Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial DataDiabetes Therapy · 2020
18. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohortTyöväentutkimus Vuosikirja · 2020
19. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in FinlandAdvances in Therapy · 2020
20. Computer‐aided 3D analysis of anatomy and radiographic parameters of the distal radiusClinical Anatomy · 2020